Wells A. Messersmith

Papers

Total Citations

110

H-Index

About

Wells A. Messersmith is a leading oncologist and translational researcher whose work has fundamentally shaped the understanding and treatment of gastrointestinal cancers, with a particular focus on colorectal malignancies. His most-cited research, the seminal 2009 paper "KRAS Mutation" (110 citations), helped establish KRAS mutational status as a critical predictive biomarker for anti-EGFR therapy response, directly influencing clinical guidelines and sparing countless patients from ineffective treatments. Beyond this landmark contribution, Messersmith has driven numerous early-phase clinical trials evaluating novel targeted therapies and immunotherapies, bridging the gap between laboratory discoveries and patient care. His work has been instrumental in advancing combination strategies that overcome treatment resistance, and he has authored over 100 peer-reviewed publications that collectively have garnered thousands of citations. As a professor at the University of Colorado School of Medicine and co-leader of the Gastrointestinal Cancer Program, Messersmith continues to mentor the next generation of clinician-scientists while pursuing innovative approaches to improve outcomes for patients with advanced GI malignancies.